Follow us

Alan Montgomery

Partner, Co-Head Pharmaceuticals, Co-Head of India Practice
London India Group

Alan specialises in public and private cross-border mergers and acquisitions, restructurings, joint ventures and partnership matters, acting for international corporates, investment banks and professional services firms.  

Alan is Co-Head of our Pharmaceuticals sector team and Co-Head of our India practice. 


Alan is ranked as a leading M&A lawyer in the London market and one of the top 10 international lawyers for India-related M&A work.


“Alan is the best I have engaged and will go back to him for all M&A needs. He is thorough in research and execution. Most issues handled were complex and came with convoluted facts Alan's ability to grasp and translate these to strategy and end product for us was fantastic. He has made the difference between ordinary to outstanding, always made us look good and negotiated with confidence and delivered on all counts.” IFLR 1000 2016

Alan Montgomery is lauded as "amongst the most dependable quality legal professionals, with the ability to analyse a matter in all its perspectives, quickly." Chambers Asia Pacific 2016

Alan is "very committed, hard-working and quick in response, immaterial of the time of day." Chambers Global 2016

Experience & expertise

Selected matters

  • Lupin on its US$600 million disposal of Kyowa Pharmaceutical to Unison
  • Strides Pharma Science on the disposal of its Australian business, Arrow Pharmaceuticals, to Arrowtex for AUD394 million
  • Sterling Pharma Solutions on its disposal to GHO
  • Aurobindo Pharma on its acquisition of Apotex's commercial operations across five European countries. The transaction includes a portfolio of over 200 prescription drugs and 88 OTC products and an additional pipeline of over 20 products
  • Claris Life Sciences Limited on the sale of its Global Generic Injectables Business to Baxter for US$625 million
  • Bharti Airtel on its US$10.7 billion acquisition of Zain Africa
  • Strides Shasun on:
    • the disposal for up to US$1.75 billion of Agila Specialties, its generic speciality injectables business, to Mylan
    • its AU$375million sale of Ascent Pharmahealth to Watson Pharmaceuticals
  • Aurobindo Pharma on its acquisition of the commercial operations of Actavis in seven European countries
  • Cipla on various significant pharmaceutical joint ventures in Africa and the Middle East
  • Abbott on a variety of matters
  • Sierra Rutile Limited on the public takeover offer made by Iluka Resources
  • United Breweries on the £1.28 billion investment by Diageo in United 
  • Ernst & Young, as administrators of Nortel's EMEA entities in connection with the disposals of Nortel's global Enterprise Solutions and GSM/GSMR businesses for over US$1 billion
  • Central SAFE Investments on the sale of a 10% strategic interest in the Bank of China to a group of investors led by Royal Bank of Scotland for approximately US$3.1 billion
  • Bharti Airtel on the disposal of its telecoms operations in Burkina Faso and Sierra Leone to Orange
  • Genus plc a UK listed biotech company on a range of corporate matters
  • VTB on the £900 million public offer by Essar Global for Essar Energy plc
  • Pala Investments Limited on its public  takeover of Sierra Rutile Limited
  • Biffa on the contested £1.23 billion takeover offer from a consortium led by Montagu Private Equity and Global Infrastructure Partners
  • HP Bulmer plc on its takeover by Scottish & Newcastle; Standard Chartered on its £440 million takeover of Axon Group plc
  • Morgan Stanley on Severstal’s unsolicited offer for Celtic Resources Holdings plc
  • Severn Trent plc on its demerger and subsequent listing of Biffa
  • BP plc on the sale of its 2% stake in Sinopec on public markets for US$742 million and on the sale of its 2% stake in PetroChina Company on public markets for US$1.65 billion